FACT: a randomised controlled trial to assess the feasibility of QbTest in the assessment process of attention deficit hyperactivity disorder (ADHD) for young people in prison—a feasibility trial protocol. Issue 1 (20th January 2020)

• Record Type: Journal Article
• Authors: Lennox, Charlotte; Hall, Charlotte Lucy; Carter, Lesley-Anne; Beresford, Bryony; Young, Susan; Kraam, Abdullah; Brown, Nikki; Wilkinson-Cunningham, Lloyd; Reeves, Mindy; Chitsabesan, Prathiba
• Is Part Of: BMJ open. Volume 10:Issue 1(2020)
• Publication Date: 2020-01-20
• Subjects: child & adolescent psychiatry -- forensic psychiatry -- clinical trials -- qualitative research; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-035519
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: The prevalence of attention deficit hyperactivity disorder (ADHD) within the Children and Young People Secure Estate (CYPSE) is much higher than seen in the general population. To make a diagnosis of ADHD, clinicians draw on information from multiple sources, including parents and teachers. However, obtaining these is particularly difficult for young people in the secure estate. There is increasing evidence in the community that QbTest is able to assist in the accurate and earlier diagnosis of ADHD. The objective of this study is to assess the feasibility and acceptability of QbTest in the assessment of ADHD within the CYPSE. Methods and analysis: A single-centre parallel group feasibility randomised controlled trial will be conducted. Sixty young people within the CYPSE identified as displaying possible symptoms of ADHD will be randomised to the intervention arm (n=30; QbTest plus usual care) or control arm (n=30; usual care). Primary analyses will be descriptive and a process evaluation will be conducted to assess the contexts involved in implementing the intervention. Interviews will be conducted to explore acceptability and thematic analysis will be used to analyse the data. Ethics and dissemination: This study was approved by National Health Service Wales research ethics committee 3 (18/WA/0347) on 15 February 2019. The findings will be published in peer-reviewed journals, presented at relevant conferences and disseminated to the public via summaries cocreated with our patient and public involvement group. Trial registration number: ISRCTN17402196